Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Change in Cash (2016 - 2025)

Protalix BioTherapeutics has reported Change in Cash over the past 16 years, most recently at $1.0 million for Q4 2025.

  • Quarterly results put Change in Cash at $1.0 million for Q4 2025, up 113.51% from a year ago — trailing twelve months through Dec 2025 was -$5.1 million (down 31.13% YoY), and the annual figure for FY2025 was -$5.1 million, down 31.13%.
  • Change in Cash for Q4 2025 was $1.0 million at Protalix BioTherapeutics, up from -$4.2 million in the prior quarter.
  • Over the last five years, Change in Cash for PLX hit a ceiling of $28.3 million in Q4 2021 and a floor of -$27.8 million in Q3 2023.
  • Median Change in Cash over the past 5 years was $365500.0 (2025), compared with a mean of -$179250.0.
  • Biggest five-year swings in Change in Cash: soared 498.96% in 2021 and later crashed 1511.95% in 2022.
  • Protalix BioTherapeutics' Change in Cash stood at $28.3 million in 2021, then plummeted by 77.45% to $6.4 million in 2022, then plummeted by 49.52% to $3.2 million in 2023, then crashed by 337.1% to -$7.6 million in 2024, then soared by 113.51% to $1.0 million in 2025.
  • The last three reported values for Change in Cash were $1.0 million (Q4 2025), -$4.2 million (Q3 2025), and -$1.6 million (Q2 2025) per Business Quant data.